Danaher Corporation vs Gitlab Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Gitlab Inc trades at $40.65 (market cap $7.11B). The key difference: Danaher Corporation is far larger — about 20.5× Gitlab Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| DHR | GTLB | |
|---|---|---|
Market Cap | $145.83B | $7.11B |
Sector | Health | Technology |
52-Week High | $242.05 | $51.04 |
52-Week Low | $161.91 | $19.42 |
Enterprise Value | $168.04B | $5.85B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
GitLab (GTLB) trades at $40.93, up 0.49% today, with a bullish technical signal from moving averages but overbought RSI readings above 90. The company reported strong revenue growth, reaching $759 million in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights its leadership in DevSecOps and AI-driven platform enhancements, including the launch of GitLab 19.2 and a collaboration with Google Cloud.
Outlook remains mixed; analyst consensus is cautious with a $32.92 price target below the current price, citing high valuation multiples like a P/E of 521.22. Risks include persistent negative cash flow and profitability challenges, though growth in AI and enterprise adoption offers long-term potential. Investors should weigh high valuation against robust revenue expansion and market position.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →